Food & Drug Administration approved Vyleesi, bremelanotide, to treat HSDD in premenopausal women after reviewing clinical trial results that demonstrated medication safety and effectiveness
One additional product passed the same testing and was Approved through CL's voluntary Quality Certification Program
Comparing Prescription vs
It also complements vitamin E, which helps reduce the oxidation of unsaturated fatty acids, supports the integrity of cell membranes, promotes the health of skin and blood cells, and helps lower free radical formation with its antioxidant effects
[28] Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, Marder K, Naini A, Stern Y, Mayeux R.Arch Neurol
Bracchiglione J, Meza N, Franco JV, et al